drugset / Trial / NCT05584332
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
RandomizedParallel-groupDouble-blindPrevention
Summary
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .
Timeline
- Start
- 2022-12-09
- Primary completion
- 2023-03-23
- Completion
- 2023-03-23
Outcome
Outcome not reported
Stopped (Business): “Strategic adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) | Vaccine | 0.5 ml | — |